Pharmaceutical News

RSS

Nigeria approves misoprostol for use in hospitals and clinics

An old drug will gain a new use in Nigeria when misoprostol will be distributed for prevention and control of post-partum hemorrhage, the life-threatening bleeding after childbirth that commonly occurs in developing countries.

3 Apr 2006

ADHD drug not safe for kids

According to a panel of experts advising the U.S. Food and Drug Administration (FDA), the drug Provigil, although effective in treating attention deficit hyperactivity disorder (ADHD) in children and teenagers, is not safe enough to win approval.

26 Mar 2006

Asthma drug approved for children age four up

The U.S. Food and Drug Administration (FDA) has given approval for the use of the asthma drug Flovent HFA in children four to eleven years of age.

26 Mar 2006

Remicade (infliximab) gains Australian approval for treatment of early rheumatoid arthritis

Schering-Plough Corporation today announced that the Therapeutic Goods Administration of the Department of Health and Ageing in Australia has revised the indication of Remicade (infliximab) to include the treatment of early rheumatoid arthritis (RA) and approved a new indication for psoriatic arthritis (PsA).

23 Mar 2006

Avicena receives orphan drug designation for Huntington's disease

The Avicena Group has announced today that the United States Food and Drug Administration (FDA) has granted orphan drug designation to HD-02, the company's proprietary drug candidate for the treatment of Huntington's disease.

23 Mar 2006

U.S. buys more Relenza and Tamiflu for future influenza pandemics

The United States Department of Health and Human Services has announced additional purchases of antiviral drugs that could be used in the event of a potential influenza pandemic.

23 Mar 2006

ChemGenex Pharmaceuticals receives U.S. orphan drug designation for Ceflatonin

ChemGenex Pharmaceuticals has announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug status for the company's most advanced drug, Ceflatonin, for the treatment of chronic myeloid leukemia (CML).

21 Mar 2006

FDA grants Cerexa fast track designation

Cerexa has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PPI-0903, a next-generation, broad-spectrum, cephalosporin antibiotic, for the treatment of complicated skin and skin structure infections (cSSSI) caused by methicillin-resistant Staphylococcus aureus (MRSA).

17 Mar 2006

GlaxoSmithKline receives NDA for Coreg CR

GlaxoSmithKline has announced that the new drug application (NDA) for Coreg CR has been accepted for review by the U.S. Food and Drug Administration (FDA).

17 Mar 2006

Drug trial nightmare - two still critically ill

In the drug trial nightmare which has left six men very ill in a London Hospital two remain in intensive care and are not expected to make any early improvement, according to their doctor Ganesh Suntharalingham, Northwick Park Hospital's Clinical Director of Intensive Care.

17 Mar 2006

Lives in danger as drug trial goes horribly wrong

In a drug trial which went horribly wrong two men are critically ill in a London hospital and four others are seriously ill, after suffering violent reactions to a new drug they took as part of a clinical trial.

16 Mar 2006

Drug trial goes wrong and six end up intensive care

After taking part in a clinical trial of a new drug six men are now seriously ill in a north London hospital in the UK.

15 Mar 2006

New agreement on Chinese malaria vaccine candidate

In a move that promises to expand the clinical testing of another promising malaria vaccine candidate, the US-based PATH Malaria Vaccine Initiative (MVI) and the Chinese company Shanghai Wanxing Bio-Pharmaceuticals today announced an agreement that supports the development of a pediatric malaria vaccine against Plasmodium (P.) falciparum, the most deadly strain of malaria.

15 Mar 2006

Best seller Lipitor shown to improve kidney function

According to drug maker Pfizer it's top selling product worldwide, the cholesterol lowering medication Lipitor (Atorvastatin) has been shown to improve kidney function in patients with heart disease.

13 Mar 2006

Nabi Biopharmaceuticals receives Fast Track status for nicotine vaccine

Nabi Biopharmaceuticals today announced that NicVAX (Nicotine Conjugate Vaccine), the company's novel investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA).

9 Mar 2006